ZURICH (Reuters) – Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars.
The agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances, Sandoz said in a statement.
“The terms of the agreement will not impact our previously disclosed 2024 guidance,” Sandoz said.
Patent infringement proceedings were initially filed by Amgen in the U.S. Federal District Court for the District of New Jersey in May 2023, the statement said.
(Writing by Dave Graham; Editing by Miranda Murray)
Comments